242 Phase I study of irinotecan (I), raltitrexed (R), and 5-fluorouracil (5FU) in the treatment of metastatic colorectal cancer (MCRC) refractory to thymidylate synthase inhibitors (TSI)
Rakesh Goel(Ottawa Hospital), Leslie Douglas, Derek J. Jonker(University of Ottawa), G. Chiritescu(Ottawa Hospital), Jean A. Maroun(American Society of Clinical Oncology), C. Cripps(Canadian Partnership Against Cancer), Simone Dahrouge(Ottawa Regional Cancer Foundation)
Cited by 0
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k